No Data
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): Shareholder Bai Ying has cumulatively reduced her shareholding by 0.58%.
On March 10, Gelonghui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that the company recently received a notice letter regarding the shareholding reduction results from shareholder Ms. Bai Ying. During the shareholding reduction plan period, Ms. Bai Ying cumulatively reduced her holdings by 1,100,000 shares through bulk trading, accounting for 0.58% of the company's total shares. After this reduction, Ms. Bai Ying and her concerted actors together hold 15,167,159 shares in the company, accounting for 8.002% of the total shares. As of the date of this announcement, the implementation period of this shareholding reduction plan has expired.
Research Reports to Uncover Opportunities | HAITONG SEC: Assigning Eyebright Medical Technology (Beijing) Co., Ltd. an "Outperform Market" rating, Target Price 89.30-108.16 yuan.
HAITONG SEC's Research Reports indicate that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) is expected to achieve a net income of 0.387 billion yuan (+27.36%) for the year 2024, with a net income excluding non-recurring items of 0.389 billion yuan (+34.58%). In 2024, the company's series of artificial lenses 'Punomeng' and 'Punotong' shaped corneal lenses are expected to maintain year-on-year income growth, while vision care products (such as contact lenses and contact lens care products) continue to grow rapidly, accounting for about 30% of revenue. The increase in revenue has driven the growth of the company's net income, and the contact lens business has turned profitable; however, it is affected by the price decrease following the centralized procurement of artificial lenses.
Aibo Healthcare: 688050 Aibo Healthcare 2024 Annual Performance Report
688050 Aibo Healthcare 2024 Annual Performance Report
In the fourth quarter, Eyebright Medical Technology (Beijing) Co., Ltd. saw a more than 30% decline in net profit compared to the previous quarter, due to a decrease in the prices of products under centralized purchasing and changes in revenue structure p
① The company's series of artificial lenses such as 'Punoming' and 'Punotong' corneal reshaping lenses have maintained year-on-year growth in revenue, while vision care products continue to grow rapidly, accounting for about 30% of revenue. ② The company's contact lens Business has turned losses into profits, and it is increasing related production capacity. After the completion of the fundraising investment project, an annual production capacity of 0.252 billion contact lenses and 500 million pairs of molds will be formed.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) performance brief: In 2024, the net income is 0.387 billion yuan, an increase of 27.36% year-on-year.
On February 6, Gelonghui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced its performance report for the fiscal year 2024. During this reporting period, the company achieved total operating revenue of 1.41 billion yuan, an increase of 48.22% year-on-year. Among these, revenues from the "Punoming" series of artificial lenses and the "Punotong" corneal molding lenses continued to grow compared to the previous year, while vision care products (such as contact lenses and contact lens care products) experienced rapid growth, accounting for approximately 30% of total revenue. For this reporting period, the net income attributable to the parent company's owners was 0.387 billion yuan, an increase of 27.36% year-on-year, with net income attributable to the parent company's owners, excluding non-recurring gains and losses.